Olympus 2010 Annual Report Download - page 14

Download and view the complete annual report

Please find page 14 of the 2010 Olympus annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

12 OLYMPUS 2010
1.
CAPSULE ENDOSCOPE
SYSTEM
ENDO
CAPSULE
Simply swallowing the Endo
Capsule, a pill-sized (11mm in
external diameter and 26mm in
length) capsule equipped with
a tiny camera and lights, allows
pictures to be taken of the entire
small bowel. Endo Capsule
delivers high-resolution images
equivalent to those provided by
endoscopes.
MEDICAL
SYSTEMS
BUSINESS
REVIEW OF OPERATIONS
GASTROINTESTINAL ENDOSCOPES
Sales of gastrointestinal endoscopes declined 9.8%
compared with the previous fiscal year to ¥191,948
million (US$2,133 million). Despite sales expansion in
the Chinese market and a steady sales increase through
the Value-per-Procedure (VPP) program in Japan and
its equivalent overseas, foreign currency translation
loss due to the strong yen and sluggish global economy
caused weak sales of Olympus’s mainstay high-
definition endoscope system, resulting in decreased
income in this business.
Core products in the Medical Systems Business
include both gastroenterological and surgical endo-
scopes, endotherapy devices, endoscopic ultrasound
systems and medical information systems.
Sales in the Medical Systems Business decreased
8.6% year on year to ¥350,716 million (US$3,897
million), while operating income edged down 0.2% to
¥74,929 million (US$833 million).
During the fiscal year under review, the appreciation
of the yen impacted the Medical Systems Business,
leading to a sales decrease of approximately ¥25,500
million. In addition, a change in the Gyrus Group
Limited’s fiscal term resulted in a ¥8,000 million
decrease in segment revenue. However, operating
income remained on par with the previous fiscal year
thanks to Olympus’s cost reduction efforts, mainly in
the surgical and endotherapy device fields.
The actual capsules do not
have a logo on them.
Domestic
Sales
Overseas
Sales
(Millions of yen)
1009
SALES
353,269
75,257
278,012
08
383,828
76,214
307,614
350,716
75,640
275,652